NCT06410300 Cardiopulmonary Monitoring in Lung Cancer Patients Receiving Combined Thoracic Radiotherapy and Immunotherapy
| NCT ID | NCT06410300 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Bo Lu |
| Condition | Lung Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 125 participants |
| Start Date | 2024-04-19 |
| Primary Completion | 2028-04-19 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 125 participants in total. It began in 2024-04-19 with a primary completion date of 2028-04-19.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The overall purpose of this study is to evaluate cardiopulmonary toxicity in patients with lung cancer (NSCLC or SCLC) undergoing combined thoracic radiotherapy ± chemotherapy and immunotherapy through timed monitoring and blood sample collection and to identify correlative biomarkers for predicting cardiopulmonary adverse events.
Eligibility Criteria
Inclusion Criteria: * Patient older than 18 years age * Diagnosis of locally advanced lung cancer (NSCLC or SCLC) with planned curative radiotherapy (45Gy and above) and planned consolidation immunotherapy. * Patients who are not receiving concurrent chemotherapy and radiotherapy are eligible. * Patients on a clinical trial that includes thoracic radiotherapy and immunotherapy are eligible and may be co-enrolled to this study. * ECOG performance status of 0-2 * Life expectancy of 6 months or longer * Patient able to provide a written informed consent prior to study entry Exclusion Criteria: * Prior thoracic radiotherapy to chest. * Patients are excluded if they are not candidates for curative thoracic radiotherapy or immunotherapy. * Other severe acute or chronic medical or psychiatric condition that may increase the risk associated with study participation, and in the judgment of the investigator would make the subject inappropriate for entry into this study.
Contact & Investigator
Bo Lu, MD
PRINCIPAL INVESTIGATOR
Chair, Department of Radiation Oncology
Frequently Asked Questions
Who can join the NCT06410300 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06410300 currently recruiting?
Yes, NCT06410300 is actively recruiting participants. Contact the research team at mcdanielbl@health.missouri.edu for enrollment information.
Where is the NCT06410300 trial being conducted?
This trial is being conducted at Columbia, United States, New Brunswick, United States, Rochester, United States.
Who is sponsoring the NCT06410300 clinical trial?
NCT06410300 is sponsored by Bo Lu. The principal investigator is Bo Lu, MD at Chair, Department of Radiation Oncology. The trial plans to enroll 125 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.